DEC 06, 2018 9:00 AM PST

Cell and Gene Therapy Solutions: Enabling PSC Translation Workflows

  • Field Applications Scientist, Cell Therapy, Thermo Fisher Scientific
      Tia Hexom, PhD received a doctorate in cell and molecular biology at the University of Tulane in New Orleans, LA, USA. Dissertation work involved investigating cell morphology and synaptic plasticity of hypothalamic neurons during chronic variable stress and dehydration. Followed by a post-doctoral fellowship sponsored by the NIH Institutional Research and Academic Career Advancement (IRACDA) fellowship investigating chronic variable stress in Alzheimer's disease. Part of this work utilized iPSCs from Alzheimer's and control patients which were subsequently made into neural stem cells and utilized for the development of Alzheimer's disease in vitro modeling for future drug discovery screening. Dr. Hexom subsequently entered the cell therapy field and has gained extensive experience in the production of raw material blood products, GMP medical devices and translational workflows for CART and other cell therapy work. During this time Dr. Hexom has: led production labs isolating various immune cells and stem cells for cell therapy; managed medical device GMP manufacturing and developed marketing tools for application science and CART translational workflows. In her current role at Thermo Fisher Scientific, Dr. Hexom supports customers transitioning their cell and gene therapy work to clinical applications by providing workflow guidance and personalized scientific support.

    Register now for live event or to view the webinar on demand if you cannot make the live time.
    DATE:   December 6, 2018
    TIME:    9:00am PST, 12:00pm EST
    Induced pluripotent stem cells (iPSC) intended for translational applications need to be of high quality; free of reprogramming transgenes, clear of adventitious agents, genetically stable, and functionally pluripotent.  Generation of such cells requires consistent reprogramming, defined culture reagents and comprehensive characterization.  CytoTune Sendai virus reprogramming enables consistent and robust reprogramming of diverse somatic cell types. Here we report the first off-the-shelf (CTS) Sendai virus reprogramming kit and a xeno-free workflow from fibroblast and blood cells designed for clinical and translational use. iPSCs were generated under these conditions from fibroblasts, CD34+ and T cells.  To further streamline characterization, three molecular methods PluriTest, ScoreCard, and KaryoStat were used to confirm pluripotency, trilineage differentiation potential and genome integrity of the iPS cells.  
    Learning Objectives:
    • The importance of consistent reprogramming, defined culture reagents and comprehensive characterization for generation of iPSC cells
    • Details for the first off-the-shelf (CTS) Sendai virus reprogramming kit
    • Review of three molecular methods PluriTest, ScoreCard, and KaryoStat and how they were used to confirm pluripotency
    Watch our related webinars here:

    Show Resources
    Show Resources
    • See more
    Connect with us